Rezolute, Inc.
corporate_fare Company Profile
Rezolute, Inc. (NASDAQ:RZLT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for RZLT at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- FDA Encourages Rezolute to Submit Full Data for Failed Phase 3 Drug, Offering Path Forward
- Rezolute Reports Wider Net Loss and Increased Burn, Pivots Key Trial Design After sunRIZE Failure
- Rezolute Reports Increased Loss, Significant Cash Burn, and Provides Update on Clinical Programs
- Rezolute's Phase 3 sunRIZE Study Misses Primary Endpoints for Congenital HI; Tumor HI EAP Shows Strong Positive Results
Financial Snapshot
Fiscal year ended June 30, 2026
Net Income
-$77.59M
Diluted EPS
-$0.75
Op. Cash Flow
-$64.64M
Operating Income
-$82.97M
Cash & Equivalents
$10.62M
Debt / Equity
0.00×
Shares Outstanding
96.41M sh
Source: 10-K · filed 2026-09-24 · accession 0001104659-26-110420
show_chartPrice Chart
Loading chart...
feed RZLT - Filings & News (Page 2)
RZLT
Mar 24, 2026, 7:30 AM EDT
Price at Filing:
$2.35
Real-time Price:
$3.95
Change:
+$1.60 (+68%)
Market Cap:
$379.177M
RZLT
Feb 12, 2026, 4:36 PM EST
Price at Filing:
$3.59
Real-time Price:
$3.95
Change:
+$0.359 (+10%)
Market Cap:
$379.177M
RZLT
Feb 12, 2026, 4:13 PM EST
Price at Filing:
$3.58
Real-time Price:
$3.95
Change:
+$0.370 (+10%)
Market Cap:
$379.177M
RZLT
Jan 07, 2026, 6:10 AM EST
Price at Filing:
$1.98
Real-time Price:
$3.95
Change:
+$1.97 (+99%)
Market Cap:
$379.177M